Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.0950 (-3.6%) ($5.0950 - $5.0950) on Fri. Mar. 26, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.53% (three month average) | RSI | 57 | Latest Price | $5.0950(-3.6%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -0.4% a day on average for past five trading days. | Weekly Trend | ADAP declines -0.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) EEM(58%) ARKK(53%) ACES(50%) VWO(48%) IBB(45%) | Factors Impacting ADAP price | ADAP will decline at least -2.265% in a week (0% probabilities). URA(-42%) EWP(-38%) SMH(-10%) SPLV(-6%) FIVG(-5%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.265% (StdDev 4.53%) | Hourly BBV | -0.6 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.31 | 5 Day Moving Average | $5.31(-4.05%) | 10 Day Moving Average | $5.3(-3.87%) | 20 Day Moving Average | $5.31(-4.05%) | To recent high | -25.5% | To recent low | 1.4% | Market Cap | $788m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |